Cargando…

Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting

BACKGROUND: In our experience, induction docetaxel, platinum, and fluorouracil (TPF) chemotherapy and sequential chemoradiation in locally advanced head and neck cancer lowers compliance owing to their considerable toxicity. Most of our head and neck cancer patients have locally advanced disease at...

Descripción completa

Detalles Bibliográficos
Autores principales: Gangopadhyay, Aparna, Nath, Partha, Biswas, Jaydip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462885/
https://www.ncbi.nlm.nih.gov/pubmed/26082800
http://dx.doi.org/10.3332/ecancer.2015.543
_version_ 1782375724867387392
author Gangopadhyay, Aparna
Nath, Partha
Biswas, Jaydip
author_facet Gangopadhyay, Aparna
Nath, Partha
Biswas, Jaydip
author_sort Gangopadhyay, Aparna
collection PubMed
description BACKGROUND: In our experience, induction docetaxel, platinum, and fluorouracil (TPF) chemotherapy and sequential chemoradiation in locally advanced head and neck cancer lowers compliance owing to their considerable toxicity. Most of our head and neck cancer patients have locally advanced disease at presentation. Physicians frequently prefer paclitaxel–cisplatin induction chemotherapy instead, because of better patient tolerance. MATERIALS AND METHODS: A total of 207 locally advanced head and neck cancer patients receiving paclitaxel and cisplatin prior to chemoradiation from November 2010 to October 2013 were studied retrospectively. Parameters like febrile neutropaenia, treatment compliance, and response rates were compared to our institutional retrospective data with TPF chemotherapy. Response was assessed by Response Evaluation Criteria in Solid Tumours (Recist) version 1.1. Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 during chemotherapy. Radiation Therapy Oncology Group (RTOG) acute toxicity criteria were used for assessment during chemoradiation. RESULTS: Febrile neutropaenia with paclitaxel– cisplatin was significantly lower 3.4% (7/207) versus 44.5% (73/164) with TPF chemotherapy (two-tailed P value < 0.0001). A 95.7 % (198/207) paclitaxel–cisplatin patients completed chemoradiation versus 87% with TPF. The difference was significant (two-tailed P value = 0.0070). Response rate at treatment completion with paclitaxel –cisplatin was 89.7% versus 88% with TPF chemotherapy. No significant differences were observed (two-tailed P value = 0.7007). CONCLUSION: Induction paclitaxel and cisplatin with sequential chemoradiation in locally advanced head and neck cancer is more suitable in a limited resource setting. Lower toxicity, better compliance, and comparable response are encouraging in our study cohort.
format Online
Article
Text
id pubmed-4462885
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-44628852015-06-16 Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting Gangopadhyay, Aparna Nath, Partha Biswas, Jaydip Ecancermedicalscience Research BACKGROUND: In our experience, induction docetaxel, platinum, and fluorouracil (TPF) chemotherapy and sequential chemoradiation in locally advanced head and neck cancer lowers compliance owing to their considerable toxicity. Most of our head and neck cancer patients have locally advanced disease at presentation. Physicians frequently prefer paclitaxel–cisplatin induction chemotherapy instead, because of better patient tolerance. MATERIALS AND METHODS: A total of 207 locally advanced head and neck cancer patients receiving paclitaxel and cisplatin prior to chemoradiation from November 2010 to October 2013 were studied retrospectively. Parameters like febrile neutropaenia, treatment compliance, and response rates were compared to our institutional retrospective data with TPF chemotherapy. Response was assessed by Response Evaluation Criteria in Solid Tumours (Recist) version 1.1. Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 during chemotherapy. Radiation Therapy Oncology Group (RTOG) acute toxicity criteria were used for assessment during chemoradiation. RESULTS: Febrile neutropaenia with paclitaxel– cisplatin was significantly lower 3.4% (7/207) versus 44.5% (73/164) with TPF chemotherapy (two-tailed P value < 0.0001). A 95.7 % (198/207) paclitaxel–cisplatin patients completed chemoradiation versus 87% with TPF. The difference was significant (two-tailed P value = 0.0070). Response rate at treatment completion with paclitaxel –cisplatin was 89.7% versus 88% with TPF chemotherapy. No significant differences were observed (two-tailed P value = 0.7007). CONCLUSION: Induction paclitaxel and cisplatin with sequential chemoradiation in locally advanced head and neck cancer is more suitable in a limited resource setting. Lower toxicity, better compliance, and comparable response are encouraging in our study cohort. Cancer Intelligence 2015-06-04 /pmc/articles/PMC4462885/ /pubmed/26082800 http://dx.doi.org/10.3332/ecancer.2015.543 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Gangopadhyay, Aparna
Nath, Partha
Biswas, Jaydip
Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting
title Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting
title_full Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting
title_fullStr Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting
title_full_unstemmed Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting
title_short Sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting
title_sort sequential chemoradiation in locally advanced head and neck cancer after induction chemotherapy: an induction chemotherapy schedule more suited to a limited resource setting
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462885/
https://www.ncbi.nlm.nih.gov/pubmed/26082800
http://dx.doi.org/10.3332/ecancer.2015.543
work_keys_str_mv AT gangopadhyayaparna sequentialchemoradiationinlocallyadvancedheadandneckcancerafterinductionchemotherapyaninductionchemotherapyschedulemoresuitedtoalimitedresourcesetting
AT nathpartha sequentialchemoradiationinlocallyadvancedheadandneckcancerafterinductionchemotherapyaninductionchemotherapyschedulemoresuitedtoalimitedresourcesetting
AT biswasjaydip sequentialchemoradiationinlocallyadvancedheadandneckcancerafterinductionchemotherapyaninductionchemotherapyschedulemoresuitedtoalimitedresourcesetting